Eupraxia Pharmaceuticals Common Stock Performance
| EPRX Stock | 3.44 0.06 1.78% |
On a scale of 0 to 100, Eupraxia Pharmaceuticals holds a performance score of 8. The firm shows a Beta (market volatility) of -0.81, which means possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Eupraxia Pharmaceuticals are expected to decrease at a much lower rate. During the bear market, Eupraxia Pharmaceuticals is likely to outperform the market. Please check Eupraxia Pharmaceuticals' value at risk, as well as the relationship between the kurtosis and price action indicator , to make a quick decision on whether Eupraxia Pharmaceuticals' price patterns will revert.
Risk-Adjusted Performance
8 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Eupraxia Pharmaceuticals Common are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Eupraxia Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point. ...more
Eupraxia |
Eupraxia Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 256.00 in Eupraxia Pharmaceuticals Common on September 14, 2024 and sell it today you would earn a total of 82.00 from holding Eupraxia Pharmaceuticals Common or generate 32.03% return on investment over 90 days. Eupraxia Pharmaceuticals Common is currently generating 0.5781% in daily expected returns and assumes 5.3905% risk (volatility on return distribution) over the 90 days horizon. In different words, 48% of pink sheets are less volatile than Eupraxia, and 89% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Eupraxia Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Eupraxia Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Eupraxia Pharmaceuticals Common, and traders can use it to determine the average amount a Eupraxia Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1072
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EPRX | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.39 actual daily | 47 53% of assets are more volatile |
Expected Return
| 0.58 actual daily | 11 89% of assets have higher returns |
Risk-Adjusted Return
| 0.11 actual daily | 8 92% of assets perform better |
Based on monthly moving average Eupraxia Pharmaceuticals is performing at about 8% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Eupraxia Pharmaceuticals by adding it to a well-diversified portfolio.
Things to note about Eupraxia Pharmaceuticals performance evaluation
Checking the ongoing alerts about Eupraxia Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Eupraxia Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Eupraxia Pharmaceuticals is way too risky over 90 days horizon | |
| Eupraxia Pharmaceuticals appears to be risky and price may revert if volatility continues |
- Analyzing Eupraxia Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Eupraxia Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Eupraxia Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Eupraxia Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Eupraxia Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Eupraxia Pharmaceuticals' pink sheet. These opinions can provide insight into Eupraxia Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Eupraxia Pink Sheet Analysis
When running Eupraxia Pharmaceuticals' price analysis, check to measure Eupraxia Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eupraxia Pharmaceuticals is operating at the current time. Most of Eupraxia Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eupraxia Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eupraxia Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eupraxia Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.